Ampersand Capital Partners Majority Recapitalizes New England Peptide

Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide

December 16, 2019

Biotechnology

Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.

Ampersand Capital Partners Majority Recapitalizes N2 Biomedical

June 18, 2019

Medical Devices

Ampersand Capital Partners completed a majority recapitalization of N2 Biomedical, a Bedford, Massachusetts-based provider of coating and surface treatment solutions for the medical device industry. The transaction positions N2 to accelerate growth and broaden its service offering; Ampersand also supported the appointment of Randall Sword as President and CEO while co-founders remain shareholders.

Ampersand Capital Partners Majority Recapitalizes Phosphorex

August 25, 2022

Healthcare Services

Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.

Ampersand Capital Partners Majority Recapitalizes Leinco Technologies

November 10, 2021

Biotechnology

Ampersand Capital Partners has completed a majority recapitalization of Leinco Technologies, a specialty manufacturer of life-science reagents and custom development services based near St. Louis, Missouri. The growth equity investment will fund expanded manufacturing capacity, broaden scientific capabilities and product offerings, and support Leinco's commercial and geographic expansion while leadership including founder Pat Leinert Sr. remain involved.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.